Phase I, Open Label Safety, Pharmacokinetic, and Pharmacodynamic Dose Escalation/De-escalation Study of 852A Administered Intravenously to Subjects With Refractory Solid Organ Tumors.
Phase of Trial: Phase I
Latest Information Update: 16 May 2018
At a glance
- Drugs 852A (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 11 Oct 2005 New trial record.